Headquartered in Conshohocken, Pennsylvania, Cencora, Inc. (COR) is a leading pharmaceutical services company dedicated to ...

Key Indicators: Cencora's Financial Health Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong ...

The latest sale netted about $300 million for Walgreens, and shrinks the company’s stake in Cencora to approximately 6%, down from 10%, according to a press release on Thursday. Walgreens said ...

Mizuho started coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price for the company. Robert W. Baird boosted ...

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

Feb 5 (Reuters) - Drug distributor Cencora (COR.N), opens new tab raised ... The Conshohocken, Pennsylvania-based company now expects its 2025 adjusted profit to range between $15.25 and $15. ...

Leerink Partnrs dropped their Q2 2025 EPS estimates for Cencora in a report released on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $4.08 per ...

For the next fiscal year, the company is expected to earn $16.52 per share on $339.6 billion in revenues. This represents a year-over-year change of 9.52% and 6.76%, respectively. Cencora may be ...

(AP) — Cencora, Inc. (COR) on Wednesday reported fiscal first-quarter net income of $488.6 million. The Conshohocken, Pennsylvania-based company said it had profit of $2.50 per share. Earnings ...

Cencora COR is slated to report first-quarter fiscal 2025 results on Feb. 05, before market open. In the last reported quarter, the company delivered an earnings surprise of 4.05%. COR’s ...